Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (31-40 of 357) with videos related to

Pageof 36
Sort By:
Lung Cancer (Amsterdam, Netherlands)|December 14, 2002
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLCCesare Gridelli, John Hainsworth
Expert Opinion on Emerging Drugs|November 22, 2019
New immunotherapy in the treatment of advanced renal cancerAndrea Muto, Cesare Gridelli
Translational Lung Cancer Research|February 11, 2021
Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issuesFrancesca Casaluce, Cesare Gridelli
Journal of Thoracic Disease|January 10, 2017
A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line settingCesare Gridelli, Tania Losanno
Current Oncology Reports|August 3, 2021
First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the ElderlyTania Losanno, Cesare Gridelli
Nature Reviews. Clinical Oncology|July 12, 2018
Frontline immunotherapy for NSCLC: alone or not alone?Cesare Gridelli, Francesca Casaluce
Oncology (Williston Park, N.Y.)|January 1, 2011
Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancerCesare Gridelli, Antonio Rossi
Expert Opinion on Drug Safety|March 24, 2016
Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancerTania Losanno, Cesare Gridelli
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 5, 2004
Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patientsCesare Gridelli, Matti Aapro
Journal of Thoracic Disease|January 12, 2019
"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?Alessia Spagnuolo, Cesare Gridelli
Pageof 36

Showing results (31-40 of 357) with videos related to

Sort By:
Pageof 36
Lung Cancer (Amsterdam, Netherlands)|December 14, 2002
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLCCesare Gridelli, John Hainsworth
Expert Opinion on Emerging Drugs|November 22, 2019
New immunotherapy in the treatment of advanced renal cancerAndrea Muto, Cesare Gridelli
Translational Lung Cancer Research|February 11, 2021
Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issuesFrancesca Casaluce, Cesare Gridelli
Journal of Thoracic Disease|January 10, 2017
A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line settingCesare Gridelli, Tania Losanno
Current Oncology Reports|August 3, 2021
First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the ElderlyTania Losanno, Cesare Gridelli
Nature Reviews. Clinical Oncology|July 12, 2018
Frontline immunotherapy for NSCLC: alone or not alone?Cesare Gridelli, Francesca Casaluce
Oncology (Williston Park, N.Y.)|January 1, 2011
Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancerCesare Gridelli, Antonio Rossi
Expert Opinion on Drug Safety|March 24, 2016
Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancerTania Losanno, Cesare Gridelli
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 5, 2004
Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patientsCesare Gridelli, Matti Aapro
Journal of Thoracic Disease|January 12, 2019
"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer": is there a substantial difference or not?Alessia Spagnuolo, Cesare Gridelli
Pageof 36